{
  "main_header": {
    "sid": 134241,
    "name": "Jagsonpal Pharma",
    "stock_name": "Jagsonpal Pharma",
    "full_name": "Jagsonpal Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/jagsonpal-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "208.38",
    "chg": -9.71,
    "chgp": "-4.45%",
    "dir": -1,
    "prev_price": "218.09",
    "mcapval": "1,425.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 507789,
    "symbol": "JAGSNPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE048B01035",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "61.11 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jagsonpal-pharma-134241-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Jagsonpal Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-jagsonpal-pharma-technically-bullish-or-bearish-3739975",
        "imagepath": "",
        "date": "2025-12-02 08:22:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Overview</strong></p>\n<p>As of 1 December 2025, Jagsonpal Pharma’s overall technical trend has transitioned from a clear bearish stance to a mildly bearish one. This subtle shift indicates that while the stock remains under pressure, the intensity of selling momentum has somewhat eased. The change suggests that the market may be digesting recent developments and could be preparing for a potential stabilisation or reversal, though confirmation is yet to be seen.</p>\n<p><strong>Key Technical Indicators</strong></p>\n<p>Examining the Moving Average Convergence Divergence (MACD), a widely followed momentum indicator, reveals a bearish signal on the weekly timeframe, while the monthly MACD is mildly bearish. This divergence implies that short-term momentum remains weak, but longer-..."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-technical-momentum-shifts-amid-mixed-market-signals-3739878",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/JagsonpalPharma_technicaldot_3739878.png",
        "date": "2025-12-02 08:00:50",
        "description": "Jagsonpal Pharmaceuticals has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of market indicators. Recent data reveals a transition from a bearish stance to a mildly bearish trend, with key technical parameters such as MACD, RSI, and moving averages signalling a cautious outlook for the stock within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Jagsonpal Pharma’s Evaluation Revised Amid Mixed Financial and Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-concerns-3737212",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/JagsonpalPharma_mojoScore_3737212.png",
        "date": "2025-11-30 10:24:23",
        "description": "Jagsonpal Pharma has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by a combination of valuation concerns, technical indicators, and financial trends. This adjustment comes despite the company’s notable profit growth and ongoing challenges in market performance within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Jagsonpal Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-jagsonpal-pharma-fallingrising-3721919",
        "imagepath": "",
        "date": "2025-11-22 00:38:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Jagsonpal Pharma’s stock has been on a downward trajectory over the past week, falling 4.54% while the Sensex gained 0.79% in the same period. The trend extends over longer horizons, with the stock declining 9.40% in the last month and 15.07% over the past year, contrasting sharply with the Sensex’s 10.47% gain during that timeframe. Year-to-date, the stock is down 17.78%, whereas the benchmark index has risen 9.08%. This persistent underperformance signals investor reluctance to back the stock despite broader market gains.</p>\n<p>On the day in question, the stock underperformed its sector by 1.79%, hitting an intraday low of ₹197.50, just 3.48% above its 52-week low of ₹194. The share price has now fallen for three consecutive sess..."
      },
      {
        "title": "Why is Jagsonpal Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-jagsonpal-pharma-fallingrising-3686892",
        "imagepath": "",
        "date": "2025-11-10 21:47:45",
        "description": "As of 10-Nov, Jagsonpal Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 213.20, which reflects a decrease of 2.9 or 1.34%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 5.64% over the past week. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite the company declaring positive results for the last six consecutive quarters, including a significant increase in operating profit, the stock's valuation appears expensive with a Price to Book Value of 5.9. Furthermore, the lack of domestic mutual fund investment, which stands at 0%, may indicate a lack of confidence in the stock's current price.\n\nIn the broader market context, the stock has significantly underperformed compared to the benchmark, with a return of -10.03% over the past year, while the market ..."
      },
      {
        "title": "Are Jagsonpal Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-jagsonpal-pharma-latest-results-good-or-bad-3671641",
        "imagepath": "",
        "date": "2025-11-04 19:45:39",
        "description": "Jagsonpal Pharmaceuticals has reported its financial results for Q2 FY26, showcasing notable operational performance. The company achieved a net profit of ₹10.80 crores, reflecting a substantial year-on-year growth of 102.63%. Revenue for the quarter reached ₹75.61 crores, marking a 23.06% increase compared to the same period last year. This growth outpaced the company's five-year sales compound annual growth rate (CAGR) of 14.30%, indicating a strengthening momentum in its pharmaceutical operations.\n\nThe operating margin improved to 18.79%, up from 16.67% in the previous year, driven by effective cost management and operational efficiencies. The profit after tax (PAT) margin also expanded significantly to 14.28%, the highest recorded in five quarters. The company demonstrated strong operational leverage, with operating profits before depreciation, interest, and tax rising 38.77% year-on-year.\n\nHowever, the..."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Adjusts Evaluation Score Amid Positive Financial Performance and Market Sentiment Shift",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-stock-downgraded-from-hold-to-sell-by-marketsmojo-3669619",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/JagsonpalPharma_mojoScore_3669619.png",
        "date": "2025-11-04 08:24:14",
        "description": "Jagsonpal Pharmaceuticals has recently seen a change in its evaluation score, reflecting shifts in market sentiment. The company reported strong financial results for Q2 FY25-26, including a notable return on equity and significant profit growth. However, concerns about high valuation and lack of mutual fund investment persist."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Faces Mixed Technical Trends Amid Market Evaluation Revision",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-technical-trend-changes-from-mildly-bearish-to-bearish-amid-stock-fluctuations-3668837",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/JagsonpalPharma_technicaldot_3668837.png",
        "date": "2025-11-04 08:02:03",
        "description": "Jagsonpal Pharmaceuticals, a small-cap firm in the Pharmaceuticals and Biotechnology sector, has seen a slight stock price increase. Despite a modest annual return compared to the Sensex, the company has shown significant long-term resilience, achieving a remarkable 1,399.34% return over the past five years."
      },
      {
        "title": "How has been the historical performance of Jagsonpal Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-jagsonpal-pharma-3667969",
        "imagepath": "",
        "date": "2025-11-03 22:44:35",
        "description": "Answer:\nThe historical performance of Jagsonpal Pharma shows a significant growth trajectory in its financial metrics over the years.\n\nBreakdown:\nJagsonpal Pharma's net sales increased from 158.57 crore in Mar'20 to 268.72 crore in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 166.83 crore in Mar'19 to 268.72 crore in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 11.06 crore in Mar'20 to 59.26 crore in Mar'25, with an operating profit margin that improved from 5.38% to 19.0% during the same period. Profit before tax surged from 9.00 crore in Mar'19 to 69.86 crore in Mar'25, while profit after tax rose from 7.22 crore to 55.36 crore, indicating a robust increase in profitability. The company's total assets grew from 146.95 crore in Mar'20 to 278.26 crore in Mar'25, with total liabilities also increasing fro..."
      }
    ],
    "total": 206,
    "sid": "134241",
    "stock_news_url": "https://www.marketsmojo.com/news/jagsonpal-pharmaceuticals-134241"
  },
  "announcements": [
    {
      "details": "Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr ASHOK KUMAR PATI as Additional Non-Executive Independent Director of the company w.e.f. November 14, 2019.",
      "source": "NSE",
      "caption": "Jagsonpal Pharmaceuticals Limited - Appointment",
      "datetime": "18-Nov-2019"
    },
    {
      "details": "Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 14, 2019.",
      "source": "NSE",
      "caption": "Jagsonpal Pharmaceuticals Limited - Outcome of Board Meeting",
      "datetime": "15-Nov-2019"
    },
    {
      "details": " <table><tr><td>The Exchange had sought clarification from Jagsonpal Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is enclosed. </td></tr></table>",
      "source": "NSE",
      "caption": "Reply to Clarification- Financial results",
      "datetime": "19-Sep-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has declared <strong>125%</strong> dividend, ex-date: 12 Sep 25",
          "dt": "2025-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has announced <strong>2:5</strong> stock split, ex-date: 08 Jan 25",
          "dt": "2025-01-08",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Jagsonpal Pharma technically bullish or bearish?

2025-12-02 08:22:55

Technical Trend Overview

As of 1 December 2025, Jagsonpal Pharma’s overall technical trend has transitioned from a clear bearish stance to a mildly bearish one. This subtle shift indicates that while the stock remains under pressure, the intensity of selling momentum has somewhat eased. The change suggests that the market may be digesting recent developments and could be preparing for a potential stabilisation or reversal, though confirmation is yet to be seen.

Key Technical Indicators

Examining the Moving Average Convergence Divergence (MACD), a widely followed momentum indicator, reveals a bearish signal on the weekly timeframe, while the monthly MACD is mildly bearish. This divergence implies that short-term momentum remains weak, but longer-...

Read More

Jagsonpal Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:00:50

Jagsonpal Pharmaceuticals has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of market indicators. Recent data reveals a transition from a bearish stance to a mildly bearish trend, with key technical parameters such as MACD, RSI, and moving averages signalling a cautious outlook for the stock within the Pharmaceuticals & Biotechnology sector.

Read More

Jagsonpal Pharma’s Evaluation Revised Amid Mixed Financial and Market Signals

2025-11-30 10:24:23

Jagsonpal Pharma has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by a combination of valuation concerns, technical indicators, and financial trends. This adjustment comes despite the company’s notable profit growth and ongoing challenges in market performance within the Pharmaceuticals & Biotechnology sector.

Read More

Why is Jagsonpal Pharma falling/rising?

2025-11-22 00:38:31

Recent Price Movement and Market Comparison

Jagsonpal Pharma’s stock has been on a downward trajectory over the past week, falling 4.54% while the Sensex gained 0.79% in the same period. The trend extends over longer horizons, with the stock declining 9.40% in the last month and 15.07% over the past year, contrasting sharply with the Sensex’s 10.47% gain during that timeframe. Year-to-date, the stock is down 17.78%, whereas the benchmark index has risen 9.08%. This persistent underperformance signals investor reluctance to back the stock despite broader market gains.

On the day in question, the stock underperformed its sector by 1.79%, hitting an intraday low of ₹197.50, just 3.48% above its 52-week low of ₹194. The share price has now fallen for three consecutive sess...

Read More

Why is Jagsonpal Pharma falling/rising?

2025-11-10 21:47:45

As of 10-Nov, Jagsonpal Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 213.20, which reflects a decrease of 2.9 or 1.34%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 5.64% over the past week. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite the company declaring positive results for the last six consecutive quarters, including a significant increase in operating profit, the stock's valuation appears expensive with a Price to Book Value of 5.9. Furthermore, the lack of domestic mutual fund investment, which stands at 0%, may indicate a lack of confidence in the stock's current price. In the broader market context, the stock has significantly underperformed compared to the benchmark, with a return of -10.03% over the past year, while the market ...

Read More

Are Jagsonpal Pharma latest results good or bad?

2025-11-04 19:45:39

Jagsonpal Pharmaceuticals has reported its financial results for Q2 FY26, showcasing notable operational performance. The company achieved a net profit of ₹10.80 crores, reflecting a substantial year-on-year growth of 102.63%. Revenue for the quarter reached ₹75.61 crores, marking a 23.06% increase compared to the same period last year. This growth outpaced the company's five-year sales compound annual growth rate (CAGR) of 14.30%, indicating a strengthening momentum in its pharmaceutical operations. The operating margin improved to 18.79%, up from 16.67% in the previous year, driven by effective cost management and operational efficiencies. The profit after tax (PAT) margin also expanded significantly to 14.28%, the highest recorded in five quarters. The company demonstrated strong operational leverage, with operating profits before depreciation, interest, and tax rising 38.77% year-on-year. However, the...

Read More

Jagsonpal Pharmaceuticals Adjusts Evaluation Score Amid Positive Financial Performance and Market Sentiment Shift

2025-11-04 08:24:14

Jagsonpal Pharmaceuticals has recently seen a change in its evaluation score, reflecting shifts in market sentiment. The company reported strong financial results for Q2 FY25-26, including a notable return on equity and significant profit growth. However, concerns about high valuation and lack of mutual fund investment persist.

Read More

Jagsonpal Pharmaceuticals Faces Mixed Technical Trends Amid Market Evaluation Revision

2025-11-04 08:02:03

Jagsonpal Pharmaceuticals, a small-cap firm in the Pharmaceuticals and Biotechnology sector, has seen a slight stock price increase. Despite a modest annual return compared to the Sensex, the company has shown significant long-term resilience, achieving a remarkable 1,399.34% return over the past five years.

Read More

How has been the historical performance of Jagsonpal Pharma?

2025-11-03 22:44:35

Answer: The historical performance of Jagsonpal Pharma shows a significant growth trajectory in its financial metrics over the years. Breakdown: Jagsonpal Pharma's net sales increased from 158.57 crore in Mar'20 to 268.72 crore in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 166.83 crore in Mar'19 to 268.72 crore in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 11.06 crore in Mar'20 to 59.26 crore in Mar'25, with an operating profit margin that improved from 5.38% to 19.0% during the same period. Profit before tax surged from 9.00 crore in Mar'19 to 69.86 crore in Mar'25, while profit after tax rose from 7.22 crore to 55.36 crore, indicating a robust increase in profitability. The company's total assets grew from 146.95 crore in Mar'20 to 278.26 crore in Mar'25, with total liabilities also increasing fro...

Read More

View All News